Skip to main content

Advertisement

SpringerLink
Log in

Data from Extension Trials: Denosumab and Zoledronic Acid

  • Current Therapeutics (SL Silverman, Section Editor)
  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

Abstract

Osteoporosis and fractures that occur as a result of this condition pose a huge public health problem to society and result in morbidity and mortality to individuals. Because osteoporosis is often a result of aging, many people are not aware that therapies exist to reduce the risk of fracture. Until recently, the most common therapies used to treat osteoporosis, the oral bisphosphonates, had an inconvenient and cumbersome mode of administration. Within the last 4 years, two new parenteral antiresorptive drugs to treat osteoporosis were approved by the US Food and Drug Administration. As treatment of osteoporosis may extend for many years, the collection of long-term efficacy and safety data is warranted. This paper discusses data from the extension trials of denosumab and zoledronic acid.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18:1023–31.

    Article  PubMed  CAS  Google Scholar 

  2. Harris ST, Siris E, Abbott T, et al. Reduced osteoporotic fracture risk in patients’ adherence to bisphosphonate therapy; Program & Abstracts of The Endocrine Society’s 87th Annual Meeting; 4–7 June 2005; 2005. pp. 3–382.

  3. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–65.

    Article  PubMed  CAS  Google Scholar 

  4. Black DM, Delmas PD, Eastell R, et al. Once yearly zoledronic acid for the treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–22.

    Article  PubMed  CAS  Google Scholar 

  5. •• Papapoulos S, Man Z, Mellstrom D et al. Five-Year denosumab treatment of postmenopausal women with osteoporosis: results from the first two years of the FREEDOM trial extension, Osteoporos Int, abstract OC26, ECCEO, Valencia, Spain, March 25, 2011. This is the most recent data presented from the FREEDOM trial extension.

  6. • Seeman E, Libarati C, Austin M et al. The transitory increase in PTH following denosumab administration is associated with reduced intracortical porosity: a distinctive attribute of denosumab therapy, Annual Meeting of the American Society of Bone and Mineral Research, abstract 1064, San Diego CA. September 17, 2011. This is the most plausible explanation for the continued increase in BMD during continuation of denosumab therapy.

  7. Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMH 162) in a randomized phase 2 study of postmenopausal women with low bone mineral density. J Bone Miner Res. 2007;22:1832–41.

    Article  PubMed  CAS  Google Scholar 

  8. Miller PC, Bolognese MA, Lewiecki EM et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43:222–29.

    Google Scholar 

  9. • Miller PD, Wagman RB, Peacock M et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial, J Clin Endocrinol Metab, 2011;96(2):394–402. This is the most recent peer-reviewed publication of denosumab data.

    Article  PubMed  CAS  Google Scholar 

  10. •• McClung MR, Lewiecki EM, Bolognese MA. Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial, Annual Meeting of the American Society of Bone Mineral and Research, abstract 1061, San Diego CA, September17, 2011. This is the most recent publication of denosumab long-term safety data.

  11. •• Black D, Reid I, Cauley J, et al. The effect of 3 versus 6 years of zoledronic acid treatment in osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT), Annual Meeting of the American Society of Bone Mineral and Research, Abstract 1070 and oral presentation, Toronto, Canada, October 16, 2010. This is the only presentation of ZOL extension trial data not yet published in peer-reviewed literature.

  12. • U.S. Food and Drug Administration: Reclast (zoledronic acid): Drug Safety Communication-New Contraindication and Updated Warning on Kidney Impairment. Available at http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm270464.htm. Posted September 1, 2011. This is a reminder of the potential renal toxicity of ZOL in at-risk patients.

  13. Reclast Prescribing Information. East Hanover, NJ: Novartis Pharmaceutical Corp; Jan. 2010.

Download references

Disclosure

Conflicts of interest: R.K. Dore: acts as a consultant and is on the Speakers’ Bureau for both Amgen and Novartis, the makers of denosumab and ZOL, respectively.

Author information

Authors and Affiliations

  1. David Geffen School of Medicine, Division of Rheumatology, UCLA, 18102 Irvine Blvd Suite 104, Tustin, CA, 92780, USA

    Robin K. Dore

Authors
  1. Robin K. Dore
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robin K. Dore.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dore, R.K. Data from Extension Trials: Denosumab and Zoledronic Acid. Curr Osteoporos Rep 10, 16–21 (2012). https://doi.org/10.1007/s11914-011-0082-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-011-0082-z

Keywords

Search

Navigation